Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02133625 · ClinicalTrials.gov registry record · Phase 1
A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT02133625 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 14 participants.
The verdict
NCT02133625, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The proposed investigation is a Phase 1 trial to determine the safety, tolerability, and maximum tolerated dose (MTD) of the combination of pioglitazone ( and carboplatin patients with advanced or metastatic solid malignancies.
Interventions
- DRUG carboplatin
- DRUG pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-08 |
| Est. Completion | 2026-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02133625
The ClinicalTrials.gov registry entry for NCT02133625 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which carboplatin is the first listed.
NCT02133625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02133625 about?
NCT02133625 is a clinical study titled "A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors". The proposed investigation is a Phase 1 trial to determine the safety, tolerability, and maximum tolerated dose (MTD) of the combination of pioglitazone ( and carboplatin patients with advanced or metastatic solid malignancies.
What is the current status of trial NCT02133625?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2011-08. Estimated completion is 2026-01.
What interventions are being tested in trial NCT02133625?
The interventions under investigation include: carboplatin (DRUG), pioglitazone (DRUG).
Who is sponsoring clinical trial NCT02133625?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.